M&A breaks the $200B barrier; GSK hands over $5M milestone;

@FierceBiotech: The JP Morgan mood: Damn the valuations and full speed ahead in 2015. Article | Follow @FierceBiotech

@JohnCFierce: Enanta plots a future in NASH, chasing another blockbuster. Story | Follow @JohnCFierce

> M&A accounted for more than $200 billion in deals last year, reports EvaluatePharma. But the most surprising part of that is that the industry hit that big number through a slate of smaller deals, without any megamergers to swell the figures. Story

> GlaxoSmithKline ($GSK) handed over a $5 million milestone to OncoMed Pharmaceuticals after the biotech enrolled the first biomarker-selected patient in its anti-Notch1 antibody (OMP-52M51) Phase Ia solid tumor clinical trial. Release

Medical Device News

@FierceMedDev: LabCorp-backed GeneCentric raising $20M Series B to build portfolio of molecular diagnostic tests. More | Follow @FierceMedDev

@VarunSaxena2: Tekmira stock soars on acquisition of OnCore to strengthen hep B pipeline. Story | Follow @VarunSaxena2

@EmilyWFierce: Bard loses bid to delay vaginal mesh trial proceedings. Article | Follow @EmilyWFierce

> What's next for next-gen sequencing? Everything. Editor's corner

> At JP Morgan, Stryker CEO embraces sales reps, dismisses Smith & Nephew plan to eliminate them. More

Pharma News

@FiercePharma: Could Zambian bats hold the key to curing Ebola? More | Follow @FiercePharma

@CarlyHFierce: Pfizer developing cholesterol-fighting vaccine as part of PCSK9 'franchise.' News | Follow @CarlyHFierce

> Boehringer weighs $2B-plus sale of U.S. generic biz as part of slimdown regimen. Report

> World's first inactivated Sabin polio vaccine approved by China FDA. More

> Armed with Pegasus win, AstraZeneca targets another sales boost for Brilinta. Article

Vaccines News

> Late-stage trials for Glaxo, Merck Ebola jabs could begin this month in West Africa. Story

> WHO approves MenAfriVac for routine infant immunization in sub-Saharan Africa. Report

> J&J partners with AC Immune on anti-tau Alzheimer's vaccine. More

> Pfizer developing cholesterol-fighting vaccine as part of PCSK9 'franchise.' Article

> China approves world's first inactivated Sabin polio vaccine. Item

Pharma Manufacturing News

> Hospira to close Clayton, NC, production plant. Story

> Indian state hires FDA's online education provider to train inspectors. Article

> FDA links saline supply chain mixup to patient death. News

> Piramal lines up $40M investment in equipment and technology. Item

> New FDA quality office to grade manufacturing operations. More

> Boehringer mulls sale of generic plant as stateside shakeup continues. Report

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.